Cardiome Pharma Corp., a specialty pharmaceutical company, is engaged in the development and commercialization of cardiovascular therapies. The company has two marketed, in-hospital, cardiology products, BRINAVESS and AGGRASTAT, which are commercially available in various markets outside of the United States. Products and Product Candidates BRINAVESS (vernakalant (IV)), was approved in the European Union in 2010 and is registered and approved in approximately 50 countries for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults (for non-surgery patients with atrial fibrillation of seven days or less) and for use in post-cardiac surgery patients with atrial fibrillation of three days or less. BRINAVESS is recommended as a first-line therapy in the European Society of Cardiology atrial fibrillation guidelines for the cardioversion of recent-onset atrial fibrillation in patients with no, or moderate, structural heart disease. AGGRASTAT (tirofiban HCL) is a reversible GP IIb/IIIa inhibitor (an intravenous anti-platelet drug) for use in Acute Coronary Syndrome (ACS) patients. The company acquired the ex-U.S. marketing rights to AGGRASTAT as part of the Correvio acquisition. Both BRINAVESS and AGGRASTAT are available commercially outside of the United States either directly through its own sales force in Europe or via its distributor and partner network in other parts of the world. Strategy The company’s core strategy is to create a hospital-based, profitable and sustainable pharmaceutical company through the acquisition, development and commercialization of innovative, cardiovascular products that the company believes would help patients, health care providers, and healthcare systems provide safer, more efficacious and cost effective treatments for heart disease. Main elements of its strategy include the following: expanding its product offering and product pipeline through in-licensing and/or acquisitions; successfully obtaining approval for vernakalant worldwide; successfully commercializing BRINAVESS in currently approved countries; continuing to support the worldwide marketing of AGGRASTAT; leveraging external resources; and continuing to support its pre-clinical programs in ion channel research by collaborating with external researchers many of whom have extensive knowledge and understanding of these programs. Competition The company’s competitors include Eli Lilly and Company; Johnson & Johnson/Centocor, Inc.; The Medicines Company; Merck & Co., Inc.; and MediCure Inc. History The company was founded in 1986. It was incorporated under the Company Act (British Columbia) in 1986. The company was formerly known as Nortran Resources Ltd. and changed its name to Nortran Pharmaceuticals Inc. in 1992. Further, the company changed its name to Cardiome Pharma Corp. in 2001.
cardiome pharma corp (COM:Toronto)
1441 CREEKSIDE DRIVE
Vancouver, BC V6J 4S7
|No competitor information is available for COM.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact CARDIOME PHARMA CORP, please visit www.cardiome.com. Company data is provided by Capital IQ. Please use this form to report any data issues.